Spyre Therapeutics logo

Spyre TherapeuticsNASDAQ: SYRE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

07 April 2016

Next earnings report:

09 August 2024

Last dividends:

N/A

Next dividends:

N/A
$1.03 B
-39%vs. 3y high
75%vs. sector
-vs. 3y high
-vs. sector
-31.44
-872%vs. 3y high
2%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 05 Jul 2024 20:38:17 GMT
$25.49-$0.44(-1.70%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

SYRE Latest News

Spyre Therapeutics Announces Grants of Inducement Awards
prnewswire.com03 June 2024 Sentiment: NEUTRAL

WALTHAM, Mass. , June 3, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 83,000 shares of common stock of Spyre to 3 non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan").

Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher
Zacks Investment Research06 February 2024 Sentiment: POSITIVE

After losing some value lately, a hammer chart pattern has been formed for Spyre Therapeutics (SYRE), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

What type of business is Spyre Therapeutics?

Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

What sector is Spyre Therapeutics in?

Spyre Therapeutics is in the Healthcare sector

What industry is Spyre Therapeutics in?

Spyre Therapeutics is in the Biotechnology industry

What country is Spyre Therapeutics from?

Spyre Therapeutics is headquartered in United States

When did Spyre Therapeutics go public?

Spyre Therapeutics initial public offering (IPO) was on 07 April 2016

What is Spyre Therapeutics website?

https://www.spyre.com

Is Spyre Therapeutics in the S&P 500?

No, Spyre Therapeutics is not included in the S&P 500 index

Is Spyre Therapeutics in the NASDAQ 100?

No, Spyre Therapeutics is not included in the NASDAQ 100 index

Is Spyre Therapeutics in the Dow Jones?

No, Spyre Therapeutics is not included in the Dow Jones index

When does Spyre Therapeutics report earnings?

The next expected earnings date for Spyre Therapeutics is 09 August 2024